Glenmark Pharmaceuticals has announced that a meeting of the Board of Directors will be held on January 30, 2026, to consider and approve the unaudited financial results for the Third Quarter and Nine Months ended December 31, 2025. The company has also announced a trading window closure for insiders from December 31, 2025, to February 01, 2026, for the purpose of this approval.
Board Meeting Announcement
A meeting of the Board of Directors of Glenmark Pharmaceuticals Limited is scheduled for January 30, 2026. The primary agenda is to review and approve the company’s unaudited financial results.
Financial Results Under Review
The Board will consider the Unaudited Financial Results for the Third Quarter (October-December) and Nine Months which ended on December 31, 2025.
Trading Window Closure
In compliance with regulations regarding insider trading, Glenmark Pharmaceuticals has initiated a trading window closure. Company directors and designated personnel are restricted from trading between December 31, 2025, and February 01, 2026. This closure is to ensure fairness and prevent any potential misuse of unpublished price-sensitive information during the financial results approval process.
Source: BSE
